Reata Pharmaceuticals Given New 105.00 Price Target at Stifel Nicolaus
| RETADelisted Stock | USD 109.67 3.31 2.93% |
About 62% of Reata Pharmaceuticals' investor base is looking to short. The analysis of current outlook of investing in Reata Pharmaceuticals suggests that many traders are alarmed regarding Reata Pharmaceuticals' prospects. The current market sentiment, together with Reata Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use Reata Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
Reata |
Reata Pharmaceuticals had its price objective increased by equities researchers at Stifel Nicolaus from 75.00 to 105.00 in a research note issued to investors on Wednesday, The Fly reports. Stifel Nicolaus target price indicates a potential upside of 20.95 percent from the companys previous close. Several other research analysts have also recently
Read at thelincolnianonline.com
 |
Reata Pharmaceuticals Fundamental Analysis
We analyze Reata Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Reata Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Reata Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Valuation
Current Valuation Comparative Analysis
Reata Pharmaceuticals is currently under evaluation in current valuation category among its peers. Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Reata Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Reata Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Reata Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Reata Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Reata Pharmaceuticals Related Equities
| VIR | Vir Biotechnology | 12.88 | ||||
| TERN | Terns Pharmaceuticals | 3.41 | ||||
| MDGL | Madrigal Pharmaceuticals | 0.88 | ||||
| SRPT | Sarepta Therapeutics | 1.52 | ||||
| CVAC | CureVac NV | 2.40 | ||||
| VKTX | Viking Therapeutics | 2.43 | ||||
| PTCT | PTC Therapeutics | 3.42 | ||||
| AKRO | Akero Therapeutics | 3.94 | ||||
| KRYS | Krystal Biotech | 4.59 |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Other Consideration for investing in Reata Stock
If you are still planning to invest in Reata Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Reata Pharmaceuticals' history and understand the potential risks before investing.
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges |